论文部分内容阅读
目的:观察布地奈德联合常规治疗慢性阻塞性肺疾病急性加重(AECOPD)患者的临床疗效及安全性。方法:64例AECOPD患者随机分为3组,对照组20例采用常规治疗,布地奈德组22例在常规治疗基础上加用布地奈德2 mg雾化吸入tid,泼尼松组22例在常规治疗基础上加用泼尼松片30 mg,po qd;均连续治疗7 d。比较3组患者治疗前和治疗后24 h、72 h及7 d的1s用力呼气容积(FEV1)值、呼吸困难评分和动脉血气分析变化情况,以及3组药品不良反应发生情况。结果:治疗后72 h和7 d,布地奈德组和泼尼松组患者的FEV1值和Pa O2值均明显高于对照组患者,呼吸困难评分和Pa CO2均明显低于对照组患者(P<0.05);治疗后7 d泼尼松组患者Pa CO2值明显低于布地奈德组(P<0.05)。3组患者药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:布地奈德联合常规治疗治疗AECOPD患者可明显改善患者呼吸状况,治疗效果与泼尼松相当。
Objective: To observe the clinical efficacy and safety of budesonide in combination with routine treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: Sixty-four AECOPD patients were randomly divided into three groups. In the control group, 20 cases were treated routinely. In the budesonide group, 22 cases were treated with inhaled budesonide 2 mg atomically on the basis of routine treatment. Twenty-two patients in the prednisone group On the basis of conventional treatment, prednisone 30 mg, po qd was added for 7 days. The forced expiratory volume of 1s (FEV1), dyspnea score and arterial blood gas analysis at 24 h, 72 h and 7 d after treatment were compared between the three groups, and the incidence of adverse drug reactions in the three groups were compared. Results: At 72 and 7 days after treatment, the FEV1 and Pa O2 values in the budesonide group and the prednisone group were significantly higher than those in the control group, and the dyspnea score and PaCO2 were significantly lower than those in the control group (P <0.05). PaCO 2 value in prednisone group was significantly lower than that in budesonide group on the 7th day after treatment (P <0.05). There was no significant difference between the three groups in the incidence of adverse drug reactions (P> 0.05). Conclusion: Budesonide combined with conventional treatment of AECOPD patients can significantly improve the patient’s respiratory status, the treatment effect is comparable with prednisone.